These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9181569)

  • 21. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody.
    Murali R; Kieber-Emmons T
    J Mol Recognit; 1997; 10(6):269-76. PubMed ID: 9770651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AIDS research. Debate begins over new vaccine trials.
    Cohen J
    Science; 2001 Sep; 293(5537):1973. PubMed ID: 11557856
    [No Abstract]   [Full Text] [Related]  

  • 24. Is an effective HIV vaccine feasible?
    Cohen J
    Science; 2005 Jul; 309(5731):99. PubMed ID: 15994545
    [No Abstract]   [Full Text] [Related]  

  • 25. [Artificial anti-HIV immunogens and methods of their delivery].
    Karpenko LI; Bazhan SI; Ignat'ev GM; Lebedev LR; Il'ichev AA; Sandakhchiev LS
    Vestn Ross Akad Med Nauk; 2003; (1):24-30. PubMed ID: 12608081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccines for immunodeficiency viruses.
    Robinson HL
    AIDS; 1997; 11 Suppl A():S109-19. PubMed ID: 9451974
    [No Abstract]   [Full Text] [Related]  

  • 27. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
    Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIDS vaccine development.
    Lévy JP
    Science; 1998 May; 280(5365):806-7. PubMed ID: 9599149
    [No Abstract]   [Full Text] [Related]  

  • 29. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody.
    Krauss IJ; Joyce JG; Finnefrock AC; Song HC; Dudkin VY; Geng X; Warren JD; Chastain M; Shiver JW; Danishefsky SJ
    J Am Chem Soc; 2007 Sep; 129(36):11042-4. PubMed ID: 17711286
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV type 1 coreceptors, neutralization serotypes, and vaccine development.
    Moore J; Trkola A
    AIDS Res Hum Retroviruses; 1997 Jun; 13(9):733-6. PubMed ID: 9171216
    [No Abstract]   [Full Text] [Related]  

  • 31. Antigenic complementarity among AIDS-associated infectious agents and molecular mimicry of lymphocyte proteins as inducers of lymphocytotoxic antibodies and circulating immune complexes.
    Root-Bernstein RS
    J Clin Virol; 2004 Dec; 31 Suppl 1():S16-25. PubMed ID: 15567090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.
    Maksyutov AZ; Bachinskii AG; Bazhan SI; Ryzhikov EA; Maksyutov ZA
    J Clin Virol; 2004 Dec; 31 Suppl 1():S26-38. PubMed ID: 15567091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
    Calarota SA; Weiner DB; Lori F; Lisziewicz J
    Vaccine; 2007 Apr; 25(16):3070-4. PubMed ID: 17292518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide mimotopes as candidate vaccines.
    Partidos CD
    Curr Opin Mol Ther; 2000 Feb; 2(1):74-9. PubMed ID: 11249654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AIDS/HIV. A STEP into darkness or light?
    Moore JP; Klasse PJ; Dolan MJ; Ahuja SK
    Science; 2008 May; 320(5877):753-5. PubMed ID: 18467578
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting carbohydrate antigens in HIV vaccine development.
    Pashov A; Canziani G; Macleod S; Plaxco J; Monzavi-Karbassi B; Kieber-Emmons T
    Vaccine; 2005 Mar; 23(17-18):2168-75. PubMed ID: 15755589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
    Wild J; Bojak A; Deml L; Wagner R
    Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.